- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02283060
Sleep and Cognition After Atripla to Stribild Switch
Change in Sleep Architecture and Neuropsychological Performance Following Switch From Atripla to Stribild.
Atripla and Stribild are two FDA-Approved one pill a day combination antiretroviral medications given for the treatment of HIV. Both drugs are reasonably well tolerated. However, efavirenz, a component of Atripla, is known to cause "mental" side effects.
This proposal aims to assess whether a switch from Atripla to Stribild for 12 weeks will be associated with reversal of sleep and cognitive disturbances. Demonstrating changes upon withdrawal of drug and substitution of a drug regimen not known to have an impact on sleep and cognition may represent the best option to determine whether use of efavirenz is associated with effects on sleep and cognition beyond the immediate period following initiation of drug.
Study Overview
Detailed Description
Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) and Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat) are 2 FDA-approved 'one pill once a day' combination antiretroviral medications given for the treatment of HIV. Both have a common nucleoside reverse transcriptase inhibitor (NRTI) backbone of tenofovir (TDF) and emtricitabine (FTC), but differ in the 3rd medication contained in the pill. Atripla contains a non-nucleoside reverse transcriptase (NNRTI) drug efavirenz (EFV) while Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat) contains an integrase inhibitor elvitegravir with the drug cobicistat inactive against HIV but designed to simply boost the level of elvitegravir.
Both drugs are reasonable well tolerated. However, efavirenz is known to cause 'mental' side-effects. It is known that the initial use of EFV is associated with central nervous system (CNS) toxicity. The symptoms of such toxicity include daytime sleepiness, or alternatively inability to sleep, as well as vivid dreams including nightmares. The majority of such symptoms are believed to resolve within weeks; however there is controversy as to whether residual problems persist on a long term basis. Furthermore there are now reports of long time cognitive dysfunction associated with the use of efavirenz. Whether this is related to sleep disturbance is not clear. Studies to assess this impact have primarily involved assessment of sleep and cognitive function in antiretroviral (ART)-naïve subjects as they are initiated on first time ART that includes EFV. Such studies however are confounded by a 'return to health' phenomena as HIV per se is known to cause sleep and cognitive deficits . There is controversy regarding whether use of efavirenz leads to long term disturbances in sleep and cognition. HIV per se causes sleep and cognitive deficits6 and studies which have tried to assess problems in antiretroviral-naïve subject's pre- and post- initiation of efavirenz-based regimens may be confounded by a 'return to health' phenomena.
This proposal aims to assess whether a switch from efavirenz/emtricitabine/tenofovir disoproxil fumarate to elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat will be associated with reversal of sleep and cognitive disturbances. Demonstrating changes upon withdrawal of drug and substitution of a drug regimen not known to have an impact on sleep or cognition may represent the best option to determine whether use of EFV is associated with effects on sleep and cognition beyond the immediate period following initiation of drug.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Lorna Nagamine, RN
- Phone Number: 808-692-1333
- Email: lornan@hawaii.edu
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Recruiting
- Hawaii Center for AIDS
-
Contact:
- Lorna Nagamine
- Phone Number: 808-692-1333
- Email: lornan@hawaii.edu
-
Contact:
- Debbie Ogata-Arakaki
- Phone Number: 808-692-1332
- Email: ogataara@hawaii.edu
-
Principal Investigator:
- Cecilia Shikuma, M.D.
-
Sub-Investigator:
- Bruce Soll, M.D.
-
Sub-Investigator:
- Dominic Chow, M.D., Ph.D.
-
Sub-Investigator:
- Beau Nakamoto, M.D., Ph.D.
-
Sub-Investigator:
- Kalpana Kallianpur, Ph.D.
-
Sub-Investigator:
- Tracie Umaki, Psy.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV infected
- Age 18 to 65 years
- On stable efavirenz/emtricitabine/tenofovir disoproxil fumarate regimen > 12 months
- Documented plasma HIV RNA < 50 copies/ml within 3 months of entry
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Receipt of any other antiretroviral drugs in addition to efavirenz/emtricitabine/tenofovir disoproxil fumarate within 6 months of study entry
- Any documented plasma HIV RNA > 100 copies/ml within the past 6 months prior to study entry
- Chronic hepatitis B as assessed by positive hepatitis B surface antigen [HBsAg]
- Chronic hepatitis C as assessed by positive hepatitis C antibody [HCVab], except with proof of viral clearance and normal liver function tests
- Other chronic disease which is uncontrolled or likely to interfere with study results
- Acute illness within 2 weeks of entry
- Previously documented history of OSA (obstructive sleep apnea)
- Moderate to high risk of OSA defined as BMI (Body mass index) > 30 plus two of the following: habitual snoring, gasping/choking, observed apnea while sleeping, neck circumference > 17 inches
- Severe depression based on the BDI-2 (Beck Depression Inventory - II)
- Chronic daily receipt of medications associated with potential for sleep interference (i.e. psychoactive drugs, steroids, decongestants, beta blockers)
- Any immunomodulator, HIV vaccine, any other vaccine, or investigational therapy within 30 days of study entry.
- Anticipated need for medications which are contraindicated as per Stribild package insert
- Any known contra-indication to use of Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat)
- Creatinine clearance (Cockcroft and Gault) < 70 ml/min
The following lab values:
- Hemoglobin < 9.0
- Absolute neutrophil count < 500/μL
- Platelet count < 40,000/μL
- AST (SGOT) and ALT (SGPT) > 5x ULN
- Active or recent past history (within past 5 years) of illicit substance or alcohol use or abuse which, in the judgment of the Investigator, will interfere with the patient's ability to comply with the protocol requirements
- Pregnancy or breast-feeding, intent to become pregnant during the course of the study or breast-feeding
- Patients, who, in the opinion of the Investigator, are unable to comply with the dosing schedule and protocol evaluation or for whom the study may not be advisable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stribild switch arm
Patient to be taken off Atripla and switched to Stribild (co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) -one tablet taken daily with food
|
To be administered orally, once daily with food.
Other Names:
|
Active Comparator: Atripla control arm
Patient to continue taking Atripla (co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate) - one tablet taken daily at bedtime on an empty stomach
|
To be administered orally, once daily at bedtime on an empty stomach
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in sleep architecture assessed by formal sleep study
Time Frame: 12 weeks
|
Change in sleep architecture as assessed by formal sleep study
|
12 weeks
|
Change in neuropsychological performance global and subdomain neuropsychological test scores
Time Frame: 12 weeks
|
Change in global and subdomain neuropsychological test scores
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Pittsburgh Sleep Quality Index Score
Time Frame: 12 weeks
|
12 weeks
|
Change in the frequency of use of sleep medications
Time Frame: 12 weeks
|
12 weeks
|
Change in the quality of life index score
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Integrase Inhibitors
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Tenofovir
- Emtricitabine
- Cobicistat
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Efavirenz
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Elvitegravir
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Other Study ID Numbers
- H027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthNot yet recruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Stribild
-
Radboud University Medical CenterCompleted
-
University of California, Los AngelesTulane University; Los Angeles LGBT CenterActive, not recruitingHuman Immunodeficiency VirusUnited States
-
Gilead SciencesCompletedHIV Infections | Acquired Immunodeficiency SyndromeUnited States
-
Midtown Medical Center, Tampa, FLGilead SciencesCompletedHIV | Sleep Disorders | AIDS
-
Gilead SciencesCompletedHIV Infections | HIVUnited States, Puerto Rico
-
Vancouver Infectious Diseases CentreGilead Sciences; Regina General HospitalUnknown
-
Gilead SciencesCompletedHIV Infections | Acquired Immunodeficiency SyndromeUnited States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
-
Gilead SciencesCompletedHIV Infections | Acquired Immunodeficiency SyndromeCanada, Switzerland, United States, France, Spain, Germany, Belgium, Austria, Italy, United Kingdom, Puerto Rico, Portugal
-
Gilead SciencesCompletedHIV Infections | HIVCanada, United States, Puerto Rico, Thailand, Australia, France, Belgium, United Kingdom, Germany, Italy, Austria, Mexico, Portugal, Switzerland, Denmark, Netherlands, Sweden
-
Duke UniversityCompleted